Tango Therapeutics rises on human trial nod and orphan tag for cancer drugs

Tango Therapeutics

25/01/2023 16:52

** Shares of cancer drug developer Tango Therapeutics Inc
 TNGX.O  rise 5% to $7.50
    ** U.S. Food and Drug Administration approves co's
application seeking to begin human trials for co's
investigational inhibitor drug, TNG462, to treat cancers with
certain gene-deletion related complications
    ** Co expects to initiate trials in mid-2023
    ** Additionally, co's brain tumor drug, TNG908, received
FDA's orphan drug tag, which could secure a 7-year marketing
exclusivity for the drug upon regulatory approval
    ** Stock has declined 12% in last 12 months
 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))